FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Ways FDA Can Modernize Drug Development

[ Price : $8.95]

A USC Schaeffer Center for Health Policy and Economics white paper urges FDA to take several steps it says can modernize drug deve...

FibroGen Paying $1.25 Million to SEC

[ Price : $8.95]

The Securities and Exchange Commission agrees to accept a FibroGen payment of $1.25 million to resolve a case involving tampering ...

State of Clinical Trials CTTI Meeting Summary

[ Price : $8.95]

A Clinical Trials Transformation Initiative meeting summary highlights four key issues discussed at its session on the state of cl...

FDA to Scrutinize AI-Powered Mental Health Devices

[ Price : $8.95]

FDA schedules an 11/6 Digital Health Advisory Committee meeting to examine the rise of generative artificial intelligence in digit...

Capsida Pauses Gene Therapy Trial After Death

[ Price : $8.95]

Capsida Biotherapeutics stops enrollment in its SYNRGY clinical trial that is evaluating gene therapy CAP-002 for treating STXBP1 ...

Prasad Reassumes Chief Medical/Scientific Officer Role

[ Price : $8.95]

FDA commissioner Marty Makary reinstates CBER director Vinay Prasads previous additional duties as the agencys chief medical and s...

Expanded Approval for AZs Koselugo

[ Price : $8.95]

FDA approves an expanded indication to include pediatric patients aged one and older for AstraZenecas Koselugo to treat some cases...

Non-Opioid Analgesic Development Guidance

[ Price : $8.95]

FDA publishes a draft guidance to assist in developing non-opioid analgesics to treat chronic pain.

Apollo TMS Cleared for Depressed Adolescents

[ Price : $8.95]

FDA clears a new indication for neurocare groups Apollo TMS therapy device to treat adolescents with major depressive disorder.

FDA Approves J&Js New Bladder Cancer Therapy

[ Price : $8.95]

FDA approves a Johnson & Johnson NDA for Inlexzo (gemcitabine intravesical system) for adults with non-muscle invasive bladder can...